Molecular Mechanisms of Liver Fibrosis
Molecular Mechanisms of Liver Fibrosis
批准号:
10612941
负责人:
VIJAY H. SHAH
金额:
$35.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-01 至 2027-04-30
关键词:
Alcohol consumptionAlcoholsAttenuatedBeta CellBindingBinding ProteinsBiological AssayCellular biologyCirrhosisClustered Regularly Interspaced Short Palindromic RepeatsDataDepositionDevelopmentEZH2 geneEndosomesEnhancersEpigenetic ProcessEtiologyFibrosisGene ActivationGene ExpressionGene Expression RegulationGenesGeneticGenetic TranscriptionGoalsGrowth FactorHepatic Stellate CellHi-CHistonesHumanImageIn VitroInstructionInsulinInvestigationKnock-outLiverLiver FibrosisLobuleMagnetic Resonance ElastographyMediatingModelingModificationMolecularMorbidity - disease rateMusPDGF receptor tyrosine kinasePeptidesPlatelet-Derived Growth FactorPlatelet-Derived Growth Factor alpha ReceptorPlayPopulationPortal vein structureProcessProductionProliferatingProteinsReceptor SignalingRoleSignal TransductionSignaling ProteinTechniquesTestingTransferaseTransforming Growth Factor betaVesiclecell motilitychromatin modificationepigenetic regulationfibrogenesisgene networkhistone methylationhistone methyltransferasein vivoinnovationknock-downliver injurymigrationmortalitymouse modelnovelparent grantpromoterprotein transportrecruitsingle-cell RNA sequencingtherapeutic targettraffickingtranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Hepatic stellate cell (HSC) activation encompasses aphenotype that includes enhanced migration,
proliferation, and matrix deposition. Migration is critical for coordinately situating HSC for matrix deposition
and development of cirrhosis. Our Long-Term Objectives are to understand the molecular underpinnings of
HSC biology that lead to cirrhosis with the goal of identifying therapeutic targets. Recently,we identified a
critical role of synectin in the process of HSC migration and fibrosis. Synectin is a cytosolic protein that
mediates signal transduction, vesicle trafficking, and ultimately gene expression. Synectin is chosen for this
proposal as a significant protein warranting detailed investigation because, as we demonstrate, it is
upregulated in human cirrhosis and is required for murine fibrogenesis. Mechanistically, we implicate synectin
inHSC migration through both short term receptor signaling as well as longer term epigenetic regulation of
gene expression networks. Our preliminary data show that depletion of HSC synectin reduces migration
signaling downstream of the receptor tyrosine kinase, platelet derived growth factor receptor alpha
(PDGFRα); attenuates transcription of a set of HSC activation genes including one that encodes the
multifunctional signaling protein, IGFBP3 (insulin growth factor binding protein-3); and abrogates murine
fibrosis in vivo. These important observations have led us to propose the central hypothesis that synectin
increases HSC migration and fibrosis by promoting PDGFRα signaling and by regulating a network of genes
that include IGFBP3. This hypothesis leads to the following Specific Aims: 1) Synectin promotes HSC
migration by regulating PDGFRα targeting and signal activation. Aim 1a will determine how synectin recruits
and binds specific vesicle trafficking proteins that maintain PDGFRα protein levels, target the protein to
endosomes and activate migration signaling. Aim 1b will uncover how disruption of synectin function leads to
autophagic degradation of PDGFRα and attenuated HSC migration. 2) Synectin epigenetically controls
IGFBP3 gene expression to promote HSC migration. Aim 2a will identify how synectin regulates a specific
histone methyl transferase, EZH2 and how this governs IGFBP3 gene expressionthrough histone
methylation. Aim 2b will determine how IGFBP3 production stimulates HSC migration. 3) Synectin regulates
fibrosis in vivo. Aim 3a will use a novel fibrosis regression model in mice with HSC selective modifications to
synectin and PDGFRα to further ascertain the proposed role of these proteins in vivo. Aim 3b will use a
synectin neutralizing peptide that selectively targets HSC in coordination with magnetic resonance
elastography (MRE) imaging, and mice with genetic deletion of IGFBP3 to elucidate how synectin promotes
fibrosis in vivo. In total, this proposal will utilize conceptually and technically innovative approaches and
concepts to test a novel hypothesis pertaining to synectin as a “master regulator” of HSC signals that lead to
migration and fibrosis.
RELEVANCE (See instructions):
Liver injury from alcohol and other etiologies can culminate in cirrhosis with significant associated morbidity
and mortality.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.cgh.2013.06.013
发表时间:
2014-04
期刊:
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
影响因子:
12.6
作者:
[Singal, Ashwani K., Kamath, Patrick S., Gores, Gregory J., Shah, Vijay H.]
通讯作者:
Shah, Vijay H.
DOI:
10.1002/hep.27117
发表时间:
2014-07
期刊:
Hepatology (Baltimore, Md.)
影响因子:
--
作者:
[Granzow M, Schierwagen R, Klein S, Kowallick B, Huss S, Linhart M, Mazar IG, Görtzen J, Vogt A, Schildberg FA, Gonzalez-Carmona MA, Wojtalla A, Krämer B, Nattermann J, Siegmund SV, Werner N, Fürst DO, Laleman W, Knolle P, Shah VH, Sauerbruch T, Trebicka J]
通讯作者:
Trebicka J
DOI:
10.1016/j.cld.2016.02.004
发表时间:
2016-08
期刊:
Clinics in liver disease
影响因子:
5.1
作者:
[Dunn W, Shah VH]
通讯作者:
Shah VH
Molecular Mechanisms of Liver Fibrosis
-
批准号:10407227
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2022
-
负责人:VIJAY H. SHAH
-
依托单位:
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic
-
批准号:10487453
-
项目类别:
-
资助金额:$29.71万
-
财政年份:2021
-
负责人:VIJAY H. SHAH
-
依托单位:
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic
-
批准号:10310667
-
项目类别:
-
资助金额:$36.61万
-
财政年份:2021
-
负责人:VIJAY H. SHAH
-
依托单位:
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic
-
批准号:10700154
-
项目类别:
-
资助金额:$21.04万
-
财政年份:2021
-
负责人:VIJAY H. SHAH
-
依托单位:
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography
-
批准号:10459414
-
项目类别:
-
资助金额:$38.17万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis
-
批准号:10202402
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography
-
批准号:10205237
-
项目类别:
-
资助金额:$38.17万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis
-
批准号:9791141
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis
-
批准号:10449219
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography
-
批准号:9791139
-
项目类别:
-
资助金额:$21.74万
-
财政年份:2018
-
负责人:VIJAY H. SHAH
-
依托单位:
Targeting matrix stiffness in lung and liver fibrosis
-
批准号:9165025
-
项目类别:
-
资助金额:$54.06万
-
财政年份:2016
-
负责人:VIJAY H. SHAH
-
依托单位:
Targeting matrix stiffness in lung and liver fibrosis
-
批准号:9332421
-
项目类别:
-
资助金额:$53.9万
-
财政年份:2016
-
负责人:VIJAY H. SHAH
-
依托单位:
TREAT-Mayo
-
批准号:8706608
-
项目类别:
-
资助金额:$3.5万
-
财政年份:2013
-
负责人:VIJAY H. SHAH
-
依托单位:
TREAT-Mayo
-
批准号:8693889
-
项目类别:
-
资助金额:$58.93万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
TREAT-Mayo
-
批准号:9524876
-
项目类别:
-
资助金额:$62.5万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
Molecular Mechanisms of Liver Fibrosis
-
批准号:10152468
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
Molecular Mechanisms of Liver Fibrosis
-
批准号:8466909
-
项目类别:
-
资助金额:$33.27万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
TREAT-Mayo
-
批准号:8546293
-
项目类别:
-
资助金额:$52.2万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
Molecular Mechanisms of Liver Fibrosis
-
批准号:9056498
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
Molecular Mechanisms of Liver Fibrosis
-
批准号:8841284
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2012
-
负责人:VIJAY H. SHAH
-
依托单位:
海外基金